Pre-made Monalizumab benchmark antibody ( Whole mAb, anti-KLRC1/NKG2A therapeutic antibody, Anti-CD159A/NKG2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Monalizumab biosimilar, Whole mAb, Anti-KLRC1/NKG2A Antibody: Anti-CD159A/NKG2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers.
| Products Name (INN Index) | Pre-Made Monalizumab biosimilar, Whole mAb, Anti-KLRC1/NKG2A Antibody: Anti-CD159A/NKG2 therapeutic antibody |
|---|---|
| INN Name | Monalizumab |
| Target | KLRC1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Innate Pharma,MedImmune,NCIC Clinical Trials Group,Novo Nordisk |
| Conditions Approved | NA |
| Conditions Active | Head and neck cancer,Non-small cell lung cancer,Cervical cancer,Chronic lymphocytic leukaemia,Endometrial cancer,Fallopian tube cancer,Ovarian cancer,Peritoneal cancer,Solid tumours,Haematological ma |
| Conditions Discontinued | Inflammation,Rheumatoid arthritis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | KLRC1 |
| Package |
